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Abstract
 
A defect in RelB, a member of the Rel/nuclear factor (NF)-
 
 
 
B family of transcription factors,
affects antigen presenting cells and the formation of lymphoid organs, but its role in T lympho-
cyte differentiation is not well characterized. Here, we show that RelB deficiency in mice leads
to a selective decrease of NKT cells. RelB must be expressed in an irradiation-resistant host cell
that can be CD1d negative, indicating that the RelB expressing cell does not contribute di-
rectly to the positive selection of CD1d-dependent NKT cells. Like RelB-deficient mice, 
 
aly/
aly
 
 mice with a mutation for the NF-
 
 
 
B–inducing kinase (NIK), have reduced NKT cell num-
bers. An analysis of NK1.1 and CD44 expression on NKT cells in the thymus of 
 
aly/aly
 
 mice
reveals a late block in development. In vitro, we show that NIK is necessary for RelB activation
upon triggering of surface receptors. This link between NIK and RelB was further demonstrated
 
in vivo by analyzing RelB
 
 
 
/
 
 
 
 
 
 
 
 
 
aly
 
/
 
 
 
 compound heterozygous mice. After stimulation with
 
 
 
-GalCer, an antigen recognized by NKT cells, these compound heterozygotes had reduced
responses compared with either RelB
 
 
 
/
 
 
 
 or 
 
aly
 
/
 
 
 
 mice. These data illustrate the complex in-
terplay between hemopoietic and nonhemopoietic cell types for the development of NKT
cells, and they demonstrate the unique requirement of NKT cells for a signaling pathway me-
diated by NIK activation of RelB in a thymic stromal cell.
Key words: T lymphocytes • NF-
 
 
 
B • lymphocyte development • lipid antigens • CD1
 
Introduction
 
RelB is a member of the Rel/nuclear factor (NF)
 
*
 
-
 
 
 
B
family of transcription factors, of which five family mem-
bers have been described in mammalian cells: RelA (p65),
c-Rel, RelB, NF-
 
 
 
B1 (p50), and NF-
 
 
 
B2 (p52; reference
1). The Rel/NF-
 
 
 
B family controls gene expression essen-
tial for cytokine expression, developmental processes, and
cell differentiation and survival, particularly in the immune
system (2). Rel proteins have distinct biologic roles as evi-
denced by the variety of phenotypes of gene-knockouts of
Rel family members. For example, RelA-deficient mice
exhibit embryonic lethality due to a defect in liver devel-
opment, whereas mice lacking functional c-Rel are viable,
but their mature B and T cells are unresponsive to most
mitogenic stimuli (3). RelB forms heterodimers with p50
or p52 to activate gene transcription (2). RelB-deficient
mice have a complex phenotype with a variety of defects in
their hemopoietic and immune systems. They lack a nor-
mal thymic medullary epithelium (4) and have a profound
defect in dendritic cells, particularly in the myeloid related
CD8
 
 
 
 
 
 dendritic cells (DCs; reference 5). The develop-
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B–inducing kinase.T
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ment of lymphoid organs and splenic germinal centers also
is impaired (6, 7). In addition, RelB mutant mice display a
late onset, severe and fatal multi-organ inflammation, in-
cluding splenomegaly and myeloid hyperplasia in the bone
marrow, as well as skin lesions similar to atopic dermatitis
(4, 8, 9). The inflammation observed in RelB
 
 
 
/
 
 
 
 mice is
T cell dependent, but no gross abnormalities were found in
conventional T or B lymphocyte differentiation before the
development of inflammation (10). However, the mice
were not analyzed for potential defects in the subsets of
specialized T cells that could have regulatory function.
NKT cells are one such specialized population of mature
lymphocytes. They rapidly secrete a variety of cytokines af-
ter activation, which may give them the ability to regulate
a variety of immune responses. NKT cells coexpress NK
receptors and TCRs, and they can be subdivided into at
least two major categories. First, the majority in mice ex-
presses a V
 
 
 
14-J
 
 
 
18 rearrangement with an invariant
CDR3 region (11–14) and they are positively selected by
CD1d, a nonclassical class I antigen-presenting molecule.
These cells are CD4
 
 
 
 or CD4
 
 
 
CD8
 
 
 
 (double negative,
DN), and they recognize the glycolipid 
 
 
 
-galactosylcer-
amide (
 
 
 
-GalCer) presented by CD1d (15, 16). The other
NK1.1
 
 
 
 T cell subpopulation is more heterogeneous, in-
cluding both CD1d-dependent and independent cells, a
greater percentage of CD8
 
 
 
 lymphocytes, and a more di-
verse TCR repertoire (17). CD1d-dependent NKT cells
with the invariant V
 
 
 
14 TCR can be readily distinguished
from other populations by staining with 
 
 
 
-GalCer loaded
CD1d tetramers (18, 19), because nearly all the cells with
this 
 
 
 
 rearrangement recognize 
 
 
 
-GalCer presented by
CD1d. There are several circumstances in which these cells
do not express NK1.1, however, including when they are
immature and after activation (17). Therefore, we refer to
them here as V
 
 
 
14
 
i
 
 T cells or V
 
 
 
14
 
i
 
 NKT cells.
The developmental pathway followed by V
 
 
 
14
 
i
 
 NKT
cells is now beginning to be elucidated. A number of gene
deficiencies that disrupt V
 
 
 
14
 
i
 
 NKT cell development
leave conventional T cells unaffected (17), providing evi-
dence that V
 
 
 
14
 
i
 
 NKT cell differentiation is divergent
from conventional T cells. It is believed, however, that
V
 
 
 
14
 
i
 
 NKT cells branch off from the conventional T cell
developmental pathway after random TCR rearrangement
in the thymus and subsequent positive selection by CD1d
expressing double positive thymocytes (17, 19–21).
Here we report that the development of V
 
 
 
14
 
i
 
 NKT
cells requires RelB expression in a radiation resistant host
cell, and that RelB activation requires a functional NF-
 
 
 
B–
inducing kinase (NIK). The differentiation of V
 
 
 
14
 
i
 
 NKT
cells is blocked at a relatively late stage, after acquisition of
the canonical TCR. These data therefore define a signaling
pathway in stromal cells that has a specific effect on V
 
 
 
14
 
i
 
NKT cells.
 
Materials and Methods
 
Mice and Immunizations. RelB
 
 
 
/
 
 
 
 and 
 
RelB
 
 
 
/
 
 
 
 mice, all on an
inbred C57BL/6 background, have been described previously
 
(4). C57BL/6, RAG2
 
 
 
/
 
 
 
, and 
 
 
 
2m
 
 
 
/
 
 
 
 mice were obtained from
The Jackson Laboratory. CD45.1
 
 
 
 congenic mice were pur-
chased from Taconic. The 
 
aly/aly
 
 homozygous mice and the
control 
 
aly/
 
 
 
 heterozygous mice (22) were purchased from
CLEA Japan. The 
 
aly/
 
 
 
 
 
  
 
RelB
 
 
 
/
 
 
 
 compound heterozygotes
were obtained by crossing 
 
aly/aly
 
 homozygous with 
 
RelB
 
 
 
/
 
 
 
mice and typing for the RelB-allele. Experiments were initiated
with 5 to 8-wk-old mice. RAG2
 
 
 
/
 
 
 
 mice were used at 8–12 wk
of age as recipients in the bone marrow chimera experiments. All
mice were housed and bred under specific pathogen free condi-
tions in the La Jolla Institute for Allergy and Immunology Vivar-
ium. For in vivo immunizations, 
 
 
 
-GalCer was dissolved in 0.5%
polysorbate 20 (Nikko Chemicals) in a 0.9% NaCl solution. Mice
of both sexes were immunized both intraperitoneally and intrave-
nously with either vehicle alone or 2 
 
 
 
g of 
 
 
 
-GalCer as de-
scribed previously (23). At the indicated time points, blood was
obtained from the retro-orbital plexus.
 
Reagents and Antibodies.
 
 
 
-GalCer was synthesized at the
Pharmaceutical Research Laboratories, Kirin Brewery Co., LTD.
The following mAbs were used in cytokine ELISAs: anti–IFN-
 
 
 
mAbs R4–6A2 and biotinylated XMG1.2 and anti–IL-4 mAbs
BVD4–1D11 and biotinylated BVD6–24G2. The cytokine stan-
dards consisted of the corresponding recombinant cytokines IFN-
 
 
 
(10
 
8
 
 U/mg) and IL-4 (10
 
7
 
 U/mg). The anti–mouse LT
 
 R mAb
(3C8, IgG1) was produced from a Sprague-Dawley rat immu-
nized with mouse LT R-Fc decoy protein (24). This antibody is
agonistic for induction of VCAM1 expression on mouse fibroblasts
and does not cross react with other TNFR family proteins. The
following mAbs were used for phenotypic analysis: anti-CD16/32
(2.4G2) for blocking Fc receptors, FITC or allophycocyanin
(APC)-labeled anti-TCR  (H57–597), PE-labeled anti-CD1d
(1B1), PE or PerCP-labeled anti-NK1.1 (PK136), Cy-Chrome
or FITC-labeled anti-CD4 (H129.19), APC or PerCP-labeled
anti-CD8  (53–6.7), APC-labeled anti-CD44 (IM7), and fluoro-
chrome-labeled isotype-matched controls. Adhesion molecule
expression on fibroblasts was determined using FITC-labeled
anti–VCAM-1 (429) and PE-labeled anti–ICAM-1 (3E2). Unless
otherwise mentioned, all antibodies and recombinant cytokines
were purchased from BD Biosciences.  -GalCer/CD1d tetramers
were produced as described previously (18).
Cell Preparation and Flow Cytometry. Liver mononuclear cells
were prepared as described previously (25). Cells from thymus,
spleen, and bone marrow were prepared by conventional meth-
ods. Red blood cells were removed from spleen cell suspensions
using a standard Ficoll gradient (Accurate Chemical & Scientific
Corporation). For surface staining, cells were suspended in buffer
comprised of PBS (pH 7.4) containing 2% BSA (wt/vol) and
0.02% NaN3 (wt/vol). After blocking with 2.4G2 anti-Fc R
mAb, the cells were stained at 4 C for 20 min with the labeled
mAbs, then washed and analyzed on a FACSCalibur™ (Becton
Dickinson) flow cytometer. Lymphocytes were enumerated out
of the heterogeneous cell population by electronic gating, as de-
termined by forward angle and side angle light scatter. Stainings
with   -GalCer/CD1d tetramers were performed as described
previously (18). Unloaded CD1d tetramers were used as controls.
Cytokine Assays. Cytokine levels were detected using stan-
dard sandwich ELISAs, according to the manufacturer’s protocol
(BD Biosciences). Cytokine levels are expressed as mean   SD of
culture triplicates. 
Preparation of APCs and Primary Cultures of Responder Cells.
For DC enrichment, spleen cell suspensions were incubated for
1 h with 400 U/ml of type III collagenase (Sigma-Aldrich),
washed, and allowed to adhere onto plastic of tissue culture flasksT
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at 107 cells/ml in culture medium for 1 h, 30 min at 37 C, 5%
CO2 as described previously (15). Nonadherent cells were then
removed, and adherent cells were reincubated overnight with 80
ng/ml of  -GalCer or with the vehicle only. The cells that be-
came nonadherent during the secondary culture period were re-
covered and centrifuged over a 50% Percoll gradient (Amersham
Biosciences). Such a purified population contained more than
80% of DCs, as identified by morphology and flow cytometry
(CD16/32low, CD11c , CD11blow, MHC class IIhigh). Pulsed
DCs were washed extensively before being added to the cultures.
Responder cells were prepared by depleting APCs from freshly
isolated splenocytes of C57BL/6 mice with I-Ab and CD19
mAbs using magnetic beads (Dynal). Obtained purity was  98%.
The responders were seeded at 2.5   105 cells/well in 96-well
plates. Primary APCs were pulsed for 2 to 3 h at 37 C with gly-
colipids, then irradiated (7,000 rad) and extensively washed be-
fore being added at 6   104 cells/well, as indicated in the figure
legends. Supernatants were harvested at indicated time points,
and cytokine levels were assessed by ELISA.
Generation of Bone Marrow Chimeras. T cell–depleted (using
anti-Thy1.1 mAbs) bone marrow cells (5–10   106) from RelB / ,
RelB / , or C57BL/6 mice were intravenously transferred into
 -irradiated (1,300 rad) RAG2 /  or  2m /  recipient mice.
Thymus, liver, and spleen of each recipient were analyzed 8–12
wk later for NKT cells.
Fibroblast Cultures. Fibroblasts isolated from the kidneys of
wild-type or RelB /  mice were isolated and maintained as de-
scribed previously (26, 27). Embryonic fibroblasts from aly/aly
and aly/  mice were established as described previously (28).
Cultures were maintained in Dulbecco’s minimal essential me-
dium containing 10% fetal calf serum, 100 U/ml penicillin, and
100  g/ml streptomycin (complete medium). Stimulation of cells
was performed by incubation with an agonistic anti-LT R mAb
(2  g/ml) or isotype control. 
Cell Extracts. Cells were harvested, and whole cell and nu-
clear extracts were prepared as described previously (29, 30).
Briefly, cell pellets were resuspended and lysed at 4 C for 25 min
in whole cell extract lysis buffer (20 mM HEPES, 0.4 M NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 10% glycerol, and 1 mM DTT)
containing phosphatase inhibitors (40 mM fl-glycerophosphate,
20 mM NaF, 1 mM Na3VO4, 20 mM p-nitrophenyl phosphate
[Calbiochem]); and protease inhibitors (aprotinin 10  g/ml, leu-
peptin 10  g/ml, bestatin 10  g/ml, and pepstatin 10  g/ml;
Calbiochem) and 1 mM phenylmethylsulfonyl chloride (Sigma-
Aldrich). Lysates were centrifuged at 13,000 g for 10 min at 4 C,
and the resulting supernatants were transferred to fresh tubes.
Protein concentrations in the supernatants were determined by
the Bradford assay (Bio-Rad Laboratories). 
Electrophoretic Mobility Shift Assays. Electrophoretic mobility
shift assays (EMSAs) were conducted as described previously with
a  32P labeled oligonucleotide probe corresponding to a consen-
sus NF- B binding site (29, 30). The composition of the acti-
vated NF- B complex was examined by supershift analysis with
antisera to Rel family members (Santa Cruz Biotechnology, Inc.). 
Homeostasis of CFSE-labeled Thymocytes. Thymuses were iso-
lated from CD45.1  congenic mice and single cell suspensions
were made. CD8  thymocytes were depleted using MACs beads
(Miltenyi Biotech) according to the manufacturer’s protocol. The
cells were suspended at a concentration of 10   106 cells/ml in
PBS/0.1%BSA for labeling with CFSE (Molecular Probes). 1  l
of a 5 mM CFSE stock (prepared in DMSO) was added per 1 ml
of cell suspension. The cells were then incubated for 10 min at
37 C, and the labeling reaction was stopped by adding cold PBS.
The cells were then washed and resuspended in PBS. 7   107
cells were injected into  -irradiated (700 rad) aly/aly or aly/ 
mice. Recipient mice were analyzed 1 wk after transfer. 
Statistical Analysis. Quantitative differences between two
samples were compared with the Mann Whitney U (rank sum)
test. When three groups were being compared, a Kruskal-Wallis
test was used, followed by a Dunn’s post-hoc test to determine
which mouse strain was different.
Results
V 14i NKT Cell Deficiency in RelB /  Mice. Mononu-
clear cells were isolated from the principal sites where
V 14i NKT cells are found, including thymus, spleen,
liver, and bone marrow, from both RelB /  and RelB / 
mice, and the fraction of  -GalCer/CD1d-tetramer 
TCR   cells was determined by flow cytometry (Fig. 1, A
and B). The mice analyzed were between 5 and 8 wk old,
before the full development of multi-organ inflammatory
disease. The percentage and absolute number of V 14i
NKT cells were greatly and consistently reduced in RelB / 
versus RelB /  mice in the thymus, spleen, liver (Fig. 1),
and bone marrow (unpublished data). Expression of other
membrane proteins characteristic for V 14i NKT cells,
such as IL-2R  and members of the Ly49 killer-inhibitory
receptor family, also were severely diminished in RelB / 
mice (unpublished data). Interestingly, the proportion of
V 14i NKT cells in heterozygous RelB /  mice, which do
not have inflammation, was also significantly reduced com-
pared with RelB /  mice (Fig. 1, A and B), indicating that
the observed defect in RelB /  mice is not secondary to in-
flammation. The number of conventional T cells was not
affected by RelB deficiency in any organ examined (un-
published data). Consistent with this decrease, IL-4 could
not be detected in serum of RelB /  mice upon in vivo ad-
ministration of  -GalCer (Fig. 1 C). The absence of cyto-
kine in the serum suggests a systemic defect in V 14i NKT
cell numbers, in all organs of RelB /  mice, rather than an
altered tissue distribution.
Despite the reduced number of V 14i NKT cells in
RelB /  mice, CD1d levels on antigen presenting cells
were found to be unaffected in all organs analyzed (Fig. 1
D, top panel). Furthermore, RelB /  splenocytes were
able to present  -GalCer to mouse V 14/V 8  hybrid-
omas as efficiently as RelB /  splenocytes (unpublished
data). This indicates that the reduced  -GalCer responses
in RelB /  mice are not due to a reduced ability to form
stimulating lipid-CD1d complexes at the surface of antigen
presenting cells.
RelB /  mice have been reported to have reduced
numbers of myeloid related CD8   DCs. To assess the
antigen presenting ability of DC from RelB /  mice, we
purified total DCs from the spleen and tested their ability
to stimulate responder V 14i NKT cells from the spleen
of C57BL/6 mice after stimulation with  -GalCer. Inter-
estingly, no differences in the levels of IFN-  were mea-
sured in the supernatants of those in vitro cultures with
DCs from RelB / , heterozygotes or wild-type miceT
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(Fig. 1 D, bottom panel). This indicates that there is no
intrinsic defect in the ability of RelB-deficient DCs to
present  -GalCer.
The Requirement of V 14i NKT Cells for RelB Is Not Cell
Autonomous. To determine whether the observed defect
in V 14i NKT cell number is cell autonomous, bone mar-
row chimeric mice were constructed by transfer of T cell-
depleted bone marrow cells from RelB /  or RelB / 
mice into lethally irradiated RAG2 /  recipients. 8 to
10 wk after transfer, chimeric mice were analyzed for the
presence of V 14i NKT cells. V 14i NKT cells were
present in the liver of RAG2 /  mice repopulated with
RelB /  bone marrow (Fig. 2 A). The fraction of V 14i
NKT cells among the total intrahepatic lymphocytes (Fig.
2 A) or among the gated, TCR   lymphocytes in the
liver, spleen, and thymus tissue (Fig. 2 B) was similar when
chimeric mice reconstituted with bone marrow from
RelB /  were compared with those reconstituted with
bone marrow from wild-type mice. These findings indi-
cate that the generation of V 14i NKT cells requires the
presence of a radiation-resistant host cell expressing RelB,
and that RelB expression is not required in the V 14i
NKT cell lineage or in the double-positive thymocyte that
selects these cells.
RelB Does Not Need to be Expressed by the  2m-positive
Cell Required for Positive Selection. If the RelB expressing
cell type(s) required for V 14i NKT cell development
were directly responsible for the positive selection of these
Figure 1. V 14i NKT cell
deficiency in RelB /  mice. (A)
Representative dot plots show-
ing TCR  versus  -GalCer/
CD1d tetramer binding in the
thymus and liver of RelB / ,
RelB / , or RelB /  mice. The
average percentage of V 14i
NKT lymphocytes is indicated.
Numbers are mean   SEM of 4
to 17 mice analyzed in each
group. (B) Total number of
V 14i NKT cells. Thymus,
liver, and spleen mononuclear
cells of the indicated mice were
labeled with mAbs against
TCR   and   -GalCer/CD1d
tetramers. Using the total cell
count obtained from each organ,
absolute numbers of NKT cells
(gated as shown in A) were de-
termined. Numbers are mean  
SEM of 4 to 17 mice analyzed in
each group. *Significantly differ-
ent from RelB /  (P    0.05,
Kruskal-Wallis; Dunn’s post-hoc
test),  †RelB /  versus RelB / 
(P     0.05, Kruskal-Wallis;
Dunn’s post-hoc test). (C) Mea-
surement of serum IL-4 upon in
vivo administration of  -GalCer.
RelB /  (n   7), RelB /  (n  
3), and RelB /  (n 2) mice on
the C57BL/6 background were
immunized with  -GalCer (2
 g/mouse) and analyzed 4 h af-
ter immunization for serum lev-
els of IL-4 as determined by
ELISA. (D)  -GalCer presenta-
tion by splenic DCs. (Top panel)
Purified DCs from the indicated
mice were isolated as described
and stained with anti-CD1d
mAb or isotype control and ana-
lyzed by flow cytometry. Repre-
sentative histograms for CD1d
(black) or controls (open lines)
are shown. (Bottom panel)
 -GalCer-pulsed DCs were
seeded at 6   104 cells/well with responder spleen cells from C57BL/6 mice at 2.5   105 cells/well. After 3 d of culture, IFN-  levels were assayed by
ELISA. Data represent mean   SEM of triplicate cultures. One representative experiment of three is shown.T
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1627 Elewaut et al.
lymphocytes, they should also express  2-microglobulin
( 2m), which is required for expression of CD1d on the
cell surface. Such a result, however, would contradict the
well-established finding that bone marrow–derived cells
select V 14i NKT cells (31–35). Bone marrow cells from
either  RelB /  or RelB /  donor mice therefore were
transferred to lethally irradiated  2m /  mice, and recipi-
ents were analyzed 8 to 12 wk later. In this separate series
of chimeras, the percentage of V 14i NKT cells was re-
duced approximately twofold compared with the previous
set (Figs. 2 A and 3), perhaps reflecting the use of irradi-
ated immune competent rather than irradiated RAG-defi-
cient recipients. Nevertheless, V 14i NKT cell develop-
ment was restored to comparable levels in liver, spleen,
and thymus of  2m /  recipients of either RelB /  or
RelB /  bone marrow (Fig. 3, and unpublished data).
These observations are consistent with a model in which
the RelB  stromal cell required for the full development
of V 14i NKT cells is not directly responsible for their
positive selection.
NIK Is Required for the Generation of V 14i NKT Cells.
To examine the role of molecules potentially upstream of
RelB and involved in its activation, we analyzed cells from
the alymphoplasia (aly/aly) mouse, which has a defect in
the organogenesis of lymph nodes and Peyer’s patches (22).
This strain has a spontaneous point mutation in the NIK,
although the mutant enzyme retains catalytic potential (36).
Previously, the aly/aly mouse also was reported to have a
deficiency in NKT cells, as determined by staining for
NK1.1 and TCR  expression as opposed to the use of
 -GalCer/CD1d tetramers (29, 30). As for RelB, NIK ex-
pression was found to be required in a radiation resistant
host cell that does not express CD1d, rather than in the
double positive thymocyte responsible for NKT cell posi-
tive selection, the NKT cell precursor or NKT cell itself
(37, 38). We confirmed this NIK requirement using
 -GalCer/CD1d tetramers to directly enumerate the
V 14i expressing, CD1d reactive, NKT cells. With this re-
agent, NIK mutant mice were found to have a reduced
number and proportion of V 14i NKT cells in spleen, thy-
mus, liver (Fig. 4, A and B), and bone marrow (unpublished
data). Consistent with this finding, aly/aly mice did not re-
spond to  -GalCer in vivo as assessed by cytokine release
into the serum (Fig. 4 C). The decrease in V 14i NKT
cells in aly/aly mice, however, was less severe than the
RelB defect. Furthermore, aly/  mice have normal num-
bers and function of their V 14i NKT cells (compare Figs.
1 and 4), indicating that a single copy of the wild-type NIK
gene is sufficient to support the generation of these cells.
RelB Acts Downstream of NIK. In addition to the V 14i
NKT cell defect, NIK and RelB mutant mice share defects
in secondary lymphoid organ development (22). These ob-
servations suggested that RelB may act downstream of
NIK to govern the development of V 14i NKT cells as
well as secondary lymphoid organs, although NIK also can
activate other NF- B family transcription factors (39). We
therefore performed experiments in vitro to provide evi-
dence for NIK activation of RelB. Adhesion molecules are
induced on primary fibroblasts after LT R stimulation
Figure 2. Development of CD1d-dependent V 14i NKT cells is re-
stored in bone marrow chimeras. (A) Representative staining with  -Gal-
Cer/CD1d tetramers. Bone marrow chimeric mice were made as de-
scribed in Materials and Methods, and liver mononuclear cells of the
indicated recipient mice were stained with mAb against TCR  and with
 -GalCer/CD1d tetramers. The fraction of total intrahepatic lympho-
cytes staining with  -GalCer/CD1d tetramers in RAG2 /  recipients re-
constituted with either RelB /  or RelB /  bone marrow is indicated.
The numbers represent mean   SEM of at least six individual mice in
each group. (B) Mononuclear cells of liver, spleen, and thymus were
stained with anti-TCR  and  -GalCer/CD1d tetramers, and the fraction
of CD1d tetramer  cells among the gated, TCR   lymphocytes was de-
termined. Numbers are the mean   SEM of at least six mice analyzed in
each group.
Figure 3. The RelB expressing cell required for V 14i NKT cell de-
velopment does not need to express  2m. Liver mononuclear cells of the
indicated recipient mice were stained with mAb against TCR  and with
 -GalCer/CD1d tetramers. The fraction of TCR   cells staining with
 -GalCer/CD1d tetramers in  2m /  recipients reconstituted with either
RelB /  or RelB /  bone marrow was determined. Numbers represent
mean   SEM of two to three individual mice analyzed in each group.T
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1628 RelB Signals in NKT Cell Development
with an agonistic antibody (28). This induction is defec-
tive, however, in NIK mutant aly/aly fibroblasts (28). To
determine if RelB might act downstream of NIK, we ana-
lyzed the induction of adhesion molecules on primary fi-
broblasts from wild-type and RelB mutant mice after
LT R stimulation. Interestingly, similar to aly/aly mice,
up-regulation of both ICAM-1 (Fig. 5 A) and VCAM-1
(unpublished data) were absent in RelB /  fibroblasts after
stimulation with an agonistic anti-LT R mAb. Upon
LT R triggering, however, RelB /  fibroblasts displayed a
similar degree of I B  degradation as RelB /  cells (un-
published data). To directly assess RelB activation, NF- B
DNA-binding activity was determined by EMSA using a
consensus NF- B DNA binding sequence as a probe.
Stimulation of mouse embryonic fibroblasts (MEFs) from
wild-type or aly/aly mice with an agonistic LT R anti-
body resulted in a profound activation of NF- B (Fig. 5
B), which lasted for more than 8 h. To determine the
identity of the NF- B containing complexes, supershift as-
says were performed. These assays revealed that RelB and
p65 containing complexes were present in wild-type MEFs
after LT R signaling (Fig. 5 B). By contrast, in aly/aly
MEFs, LT R stimulation did not result in RelB activa-
tion. Taken together, these data unambiguously demon-
strate that NIK is essential for RelB activation after LT R
stimulation in fibroblasts, but not for the activation of
complexes containing RelA (p65).
To determine if NIK might be required for RelB activa-
tion in vivo, we analyzed compound heterozygous mice
Figure 4. V 14i NKT cell deficiency in aly/aly mice. (A) Representa-
tive dot plots showing TCR  versus  -GalCer/CD1d tetramer staining
in thymus and liver from aly/  and aly/aly mice. Percentage of V 14i
NKT lymphocytes is indicated. Numbers are mean   SEM of four mice
analyzed in each group. (B) Total number of V 14i NKT cells. Thymus,
liver, and spleen mononuclear cells of the indicated mice were labeled
with mAbs against TCR  and  -GalCer/CD1d tetramers. Using the to-
tal cell count obtained from each organ, absolute numbers of V 14i NKT
lymphocytes (gated as shown in A) were determined. Numbers are
mean   SEM of four mice analyzed in each group. *P   0.05 Mann
Whitney U (rank sum) test. This data is representative of two separate ex-
periments in which four mice of each strain were analyzed. (C) Measure-
ment of IFN-  and IL-4 release upon in vivo administration of  -Gal-
Cer.  aly/  or aly/aly mice were immunized with  -GalCer (2  g/
mouse) and analyzed four (IL-4) and 16 h (IFN- ) after immunization.
Serum levels of IL-4 and IFN-  were tested by ELISA. Numbers are the
mean   SEM of four mice analyzed in each group.
Figure 5. LT R mediated activation of RelB through NIK. (A)
ICAM-1 induction by LT R stimulation. Fibroblasts from the kidneys of
RelB /  or RelB /  mice were stimulated with an agonistic  -LT R
mAb (2  g/ml) for 24 h. Cell surface levels of ICAM-1 were determined
by flow cytometry. Histograms representing ICAM-1 levels before (thin
line) and after stimulation (bold line) are shown. One representative ex-
ample of three independent experiments is shown. (B) NF- B/Rel bind-
ing activities in wild-type and aly/aly mice after LT R ligation. MEFs
from C57BL/6 and aly/aly mice were stimulated with an  -LT R mAb
(2  g/ml) for 8 h. Nuclear extracts were prepared from unstimulated and
LT R triggered cells. Extracts were incubated with a palindromic  B-
binding site as described in Materials and Methods. The results from addi-
tion of specific anti-sera against RelA (p65) and RelB are indicated at the
bottom. One representative experiment of three is shown.T
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obtained by back crossing aly/aly mice with RelB het-
erozygotes. As shown in Fig. 6 A, in addition to lacking
peripheral lymph nodes, RelB /  mice lack Peyer’s
patches. In agreement with previous results (22), we found
that aly/aly mice also lack Peyer’s patches. The aly/  het-
erozygotes have normal numbers of Peyer’s patches. Simi-
lar to the defect in NKT cells, however, there is haplo-
insufficiency for RelB, as RelB /  mice have a reduced
number of Peyer’s patches compared with wild-type con-
trols. Furthermore, the size of the remaining Peyer’s
patches in the RelB /  mice is reduced compared with
wild-type control mice (Fig. 6 B). In the aly/ , RelB / 
compound heterozygotes, the number of Peyer’s patches is
even further reduced compared with RelB /  heterozy-
gotes. Moreover, Peyer’s patches in the compound het-
erozygotes were dramatically reduced in size compared
with either the RelB /  or aly/  mice (unpublished data).
Therefore, these data suggest that NIK and RelB act in a
pathway in vivo that is important for the genesis of Peyer’s
patches. Similar groups of mutant mice were analyzed for
the number and function of V 14i NKT cells. The num-
ber of V 14i NKT cells was not significantly reduced in
the compound heterozygotes over the reduction observed
in RelB /  mice (unpublished data). V 14i NKT function
was assessed by measuring cytokines in the blood 6 h after
 -GalCer injection. As shown in Fig. 6 C, after injection
of   -GalCer, there was a significant reduction in the
amount of IFN-  in the blood in the compound heterozy-
gotes, even when compared with RelB /  mice. There-
fore, similar to the case for Peyer’s patch formation, NIK is
likely to act upon RelB in vivo in the development of
V 14i NKT cells.
A Developmental Block Underlies the V 14i NKT Cell De-
ficiency in NIK and RelB Mutant Mice. Most recent data
indicate that V 14i NKT cells are generated predomi-
nantly in the thymus (20, 21, 35, 40), although this point
remains controversial (41, 42). Despite this likely thymic
origin, the great majority of V 14i NKT cells in the thy-
mus may be mature cells that are not dividing (21, 35), but
which have the ability to secrete cytokines in vitro (12, 43,
44). Therefore, the decreased numbers of V 14i NKT
cells in the thymus tissue and elsewhere in the mutant mice
could reflect either a defect in the homeostasis or expan-
sion of mature V 14i NKT cells or a block in develop-
ment. We performed several experiments to distinguish
between these possibilities. First, to determine if the ob-
served V 14i NKT cell defect is related to the homeostasis
of mature cells, CD8-depleted thymocytes from CD45.1 
congenic mice were labeled with CFSE and injected into
irradiated wild-type or NIK mutant mice. The CD8-
depleted thymocyte population is enriched for V 14i NKT
cells, although the majority is CD4 single positive cells. By
avoiding positive selection in the enrichment of V 14i
NKT cells, we could circumvent the activation induced
Figure 6. In vivo requirement of NIK for RelB activa-
tion. (A) The number of Peyer’s patches depends upon
RelB and NIK. Peyer’s patches were counted in RelB / ,
aly/aly mice, and RelB/aly compound heterozygotes. Each
dot represents the number of Peyer’s patches in an individ-
ual mouse and the horizontal bar indicates the average
value. *RelB /    aly/  versus aly/  and RelB /  mice
(P   0.05, Student’s t test). (B) Development of normal
sized Peyer’s patches is RelB dependent. Shown are repre-
sentative Peyer’s patches in adult RelB / , RelB / , and
RelB /  mice. (C) Measurement of IFN-  release upon in
vivo administration of  -GalCer. RelB / , RelB /    aly/ 
compound heterozygotes and aly/  mice were immu-
nized with  -GalCer (2  g/mouse) and analyzed 16 h af-
ter immunization. Serum levels of IFN-  were tested by
ELISA. Numbers represent mean   SEM of four to six in-
dividual mice analyzed in each group. *RelB /    aly/ 
versus aly/  and RelB /  mice (P   0.05, Student’s t test).T
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cell death that this might cause (18). This protocol has
been used recently to analyze the influence of cytokines
and CD1d expression on the lymphopenia-induced prolif-
eration of V 14i NKT cells (45). aly/aly recipient mice
were analyzed for this experiment, because of the potential
secondary effects of RelB-mediated inflammation on
V 14i NKT cell biology or the postirradiation survival of
the recipients. 7 d after transfer, the recipients were killed
and the homeostatic proliferation of donor CD45.1 
V 14i NKT cells was analyzed by flow cytometry. As
shown in Fig. 7 A, V 14i NKT cells underwent three to
four cell divisions in both wild-type and aly/aly recipients.
Similarly, no differences in the homeostatic proliferation of
conventional T cells could be observed in the two types of
recipients (unpublished data).
Cells from the thymus of the mutant mice were analyzed
by multi-parameter flow cytometry to determine if a phe-
notypic alteration consistent with a defect in V 14i NKT
cell differentiation was evident. Development of V 14i
NKT cells is likely to proceed through a double positive
(DP) intermediate (21), but these cells are so rare that a dis-
crete population of tetramer  DP cells in the adult thymus
cannot be observed. NK1.1 CD44  V  14i NKT cells
have been identified as the most mature thymus subset,
however, and the data indicate that they differentiate from
a NK1.1  and CD44   -GalCer/CD1d tetramer  precur-
sor (20, 46). These markers therefore were used in order to
determine the developmental stage reached by V 14i NKT
cells in aly/aly mice. Similar to C57BL/6 mice, most
V 14i NKT cells in the thymus of adult aly/aly mice had a
NK1.1 CD44  phenotype (Fig. 7 B) indicating that the
block seen in NIK-deficient mice is likely to occur late in
V 14i NKT cell development. The proportion of CD4 
and DN NKT cells was also similar between the strains
(unpublished data). Collectively, these data suggest that the
development rather than the homeostasis of tetramer  cells
is impaired in the absence of signals mediated through NIK
and RelB.
Discussion 
The results from this study reveal two important new
features of the biology of NF- B family transcription fac-
tors containing RelB. First, the data demonstrate a selective
requirement for RelB in the differentiation of V 14i NKT
cells. The haplo-insufficiency of RelB with respect to
V 14i NKT cell differentiation indicates that the defect is
not secondary to inflammatory disease, which is not found
in RelB /  mice. Second, the results delineate an upstream
pathway for the selective activation of RelB, providing a
connection between NIK and RelB activity. This pathway
was documented in vitro, and data also were presented in-
dicating it operates in vivo as well to control the differenti-
ation of V 14i NKT cells and the formation of Peyer’s
patches. The results from several experiments are consistent
with a block at a late stage in V 14i NKT cell differentia-
tion in mutant mice that cannot activate RelB through
NIK. First,  -GalCer–reactive NKT cells were greatly re-
duced in RelB /  and aly/aly mice in all principal sites
where these cells normally are found, including the thymus
(31–35). Second, V 14i NKT cell responses could not be
detected systemically in the serum after  -GalCer stimula-
tion, suggesting that functional cells were absent, rather
than having migrated to a different location. Despite this,
CD1d surface expression and the ability of CD1d to
present a glycolipid antigen were not affected by RelB de-
ficiency. Third, the migration of CFSE-labeled thymic
V 14i NKT cells to the liver was unimpaired in aly/aly
mice, as was their homeostatic proliferation in a lym-
phopenic environment, consistent with a primary defect in
V 14i NKT cell differentiation as opposed to homeostasis
or homing. While the pathway for V 14i NKT cell devel-
opment remains incompletely characterized, the mature
phenotype of the residual V 14i NKT cells present in the
thymus of aly/aly mice is consistent with a partial block late
in differentiation. This phenotype is different, however,
from that observed in IL-15 /  mice, which have a block
in differentiation at an earlier stage, as well as effects on the
lymphopenia induced proliferationV 14i NKT cells (45).
Previous studies have demonstrated an essential role for
CD1d expressed by bone marrow–derived cells, probably
cortical CD4 CD8  thymocytes, in the positive selection of
 -GalCer–reactive NKT cells (31–35). The data here dem-
onstrate that a radiation resistant host cell that expresses RelB
also is indispensable. The results from transfer of RelB / 
Figure 7. V 14i NKT cell dif-
ferentiation, not homeostasis, is
affected by disrupting NIK signal-
ing. (A) Homeostatic prolifera-
tion of  -GalCer reactive V 14i
NKT cells. CD45.1 , CD8 de-
pleted thymocytes were labeled
with CFSE and adoptively trans-
ferred to CD45.2  aly/  or aly/
aly recipients as described. 7 d af-
ter transfer the number of cell di-
visions of CD45.1    -GalCer/
CD1d-tetramer  NKT cells in
the liver of the recipient mice was
analyzed by flow cytometry. His-
tograms representing CFSE stain-
ing in gated tetramer  cells in aly/ 
or  aly/aly recipients are shown.
One representative example of
four independent experiments is
shown. (B) Maturity of thymic
NKT cells. Thymocytes of the
indicated mice were stained with
mAbs against TCR , CD44,
NK1.1, and with  -GalCer/
CD1d tetramers. V 14i NKT
cells were gated as shown in Fig. 1
A and Fig. 3 A and analyzed for
the expression of CD44 and
NK1.1. The average percentage
of CD44 NK1.1  V  14i NKT
cells is indicated. Numbers are
mean   SEM of four (aly/aly) or
five (C57BL/6) mice analyzed in
each group.T
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bone marrow cells to  2m /  mice demonstrate that this ra-
diation-resistant host cell does not need to express CD1d.
Conversely, both the positively-selecting CD1d  thymocyte
and the NKT cell progenitor do not require RelB. Thus,
rather than being directly responsible for CD1d-mediated
positive selection, the RelB expressing cell has an indirect
role. In aly/aly mice, a similar CD1d-independent require-
ment for a NIK expressing stromal cell was reported for the
generation of NK1.1  TCR   cells (37, 38). The previous
studies did not use CD1d tetramers to detect the affected ell
population. NK1.1 expression can vary in different genetic
backgrounds making NKT cell detection problematic, and
the previous studies could not have detected immature
NK1.1  V 14i T cells, and therefore did not identify the
stage at which the differentiation of the cells was blocked.
It remains to be determined where the required interac-
tion between the maturing V 14i NKT cell and the RelB
expressing stromal cells occurs within the thymus. Transfer
of a medullary epithelial cell line into aly/aly mice resulted in
an increase in NK1.1  TCR  cells in the thymus (38), and
RelB-deficient mice have a specific defect in medullary epi-
thelial cells, as identified by UEA-1 staining (6). These find-
ings suggest that normal V 14i NKT cell development re-
quires the activity of the NIK/RelB pathway in epithelial
cells in the thymic medulla. It is noteworthy that a number
of mutations alter V 14i T cell differentiation while having
only a minimal or no effect on conventional T cells (for a re-
view, see reference 17). The complexity of the gene pro-
gram required to produce V 14i T cells probably reflects the
combined genetic requirements for conventional positive se-
lection as well as the requirements for the subsequent activa-
tion and expansion of these V 14i T cells in the thymus.
Despite the obvious importance of RelB for the immune
system, scarce data are available on its regulation and the
upstream receptors that might be responsible for its activa-
tion. The basal NF- B activity in thymus and spleen
largely consists of p50-RelB and p52-RelB heterodimers,
as opposed to the inducible NF- B binding activity, which
often consists of RelA (p65) and c-Rel containing com-
plexes (47–50). It was therefore believed that RelB primar-
ily had a role in the constitutive expression of NF- B–
dependent genes (47–49). RelB activation has been shown
in vitro, however, by stimulation of primary B cells with
CD40L (51, 52). This activation was found to be selective
to stimulation through the TNF family receptor CD40, as
opposed to other stimulatory signals, but the in vivo signif-
icance of this pathway remains to be determined. Stimula-
tion of MEFs through the LT -R has been shown to lead
to RelB translocation to the nucleus as well. RelB is se-
questered in the cytosol by the p100 molecule. Upon stim-
ulation through the LT -R, p100 is processed into p52,
and the p52-RelB complex can subsequently be found in
the nucleus. This translocation was found to require the ac-
tion of IKK  (53–55).
Here we have demonstrated that LT R ligation results
in sustained NF- B DNA binding with a unique composi-
tion of Rel complexes, consisting of both RelA and RelB
DNA binding complexes. Interestingly, by contrast with
RelA, we have shown that the activation of RelB is strictly
dependent upon functional NIK in vitro. Although the
analysis of compound heterozygotes is complicated by the
haplo-insufficiency of RelB, enhanced defects in Peyer’s
patch formation and V 14i NKT cell function in RelB and
aly compound heterozygotes suggests that this pathway also
is important in vivo. The role of RelB in lymphoid devel-
opment, however, is independent from its proinflammatory
role, as aly/aly mice do not develop inflammation. Our data
are consistent with those from a recent study demonstrating
that cells with a null mutation of NIK displayed normal
NF- B DNA binding activity when treated with TNF or
LT R antibodies (39). However, NIK was selectively re-
quired for MCP-1 gene transcription induced through liga-
tion of the LT R, but not TNF receptors (39). Altogether,
the results suggest that NIK activity is induced by a subset
of TNF family receptors, and that it in turn selectively reg-
ulates the transcriptional activity NF- B family members.
RelB forms active heterodimers with two NF- B sub-
units, p50 and p52, and the question arises whether the in-
flammatory versus developmental roles can be ascribed to
the different RelB-containing heterodimers. Defects in
secondary lymphoid tissue formation have been reported in
p52 but not in p50-deficient mice (56, 57). Interestingly,
the processing of p100 by NIK to generate p52 (58) has
been recently reported using gene overexpression systems.
These results, together with the data presented here, sug-
gest that RelB-p52 activation, perhaps through NIK by
p100 processing, may be essential for aspects of lymphoid
development as well as V 14i T cell differentiation. The
increased inflammatory phenotype observed in RelB / 
p50 /  mice, compared with RelB /  mice, suggests that
the lack of RelB is in part compensated by other p50-con-
taining complexes (59). However, p50 complexes that do
not contain RelB have not been characterized. Further-
more, other mechanisms have been proposed by which
RelB might control inflammation, such as regulation of
stability of the inhibitor protein I B  (60).
In summary, we have shown that RelB activation
through NIK is an essential mediator of V 14i NKT cell
differentiation and Peyer’s patch formation in vivo. In
V 14i NKT cell development, this pathway is required on
a thymus stromal cell that is not directly required for
CD1d-mediated positive selection. These findings demon-
strate the interplay between hemopoietic and nonhemo-
poietic cells in the unique pathway governing the develop-
ment of V 14i NKT cells.
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